Literature DB >> 7569499

Planning and revising the sample size for a trial.

A L Gould1.   

Abstract

The sample size for a trial depends on the type I and type II error rates and on the minimum relevant clinical difference, all of which are known, and on the anticipated, but unknown, value of a measure of variation for the key response. This measure is the overall response rate when the key response is binomially distributed, or the residual variance in each treatment group when the key response is continuous and normally distributed. Since the true value of the measure is unknown, it must be guessed or estimated from previous trials. We describe approaches to determine an appropriate value for it, both before the trial begins and after it has begun, for use in calculating the final sample size. These approaches differ from previously described 'internal pilot' methods in not requiring unblinding of the treatment assignments in the trial. They preserve the power and do not affect the type I error rate materially. The approaches can be applied to longitudinal studies where the rate of change over time is the response of interest, and to group sequential trials.

Entities:  

Mesh:

Year:  1995        PMID: 7569499     DOI: 10.1002/sim.4780140922

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  16 in total

1.  The Adaptive designs CONSORT Extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design.

Authors:  Munyaradzi Dimairo; Philip Pallmann; James Wason; Susan Todd; Thomas Jaki; Steven A Julious; Adrian P Mander; Christopher J Weir; Franz Koenig; Marc K Walton; Jon P Nicholl; Elizabeth Coates; Katie Biggs; Toshimitsu Hamasaki; Michael A Proschan; John A Scott; Yuki Ando; Daniel Hind; Douglas G Altman
Journal:  BMJ       Date:  2020-06-17

2.  Group sequential extensions of a standard bioequivalence testing procedure.

Authors:  A L Gould
Journal:  J Pharmacokinet Biopharm       Date:  1995-02

3.  Twenty-five years of confirmatory adaptive designs: opportunities and pitfalls.

Authors:  Peter Bauer; Frank Bretz; Vladimir Dragalin; Franz König; Gernot Wassmer
Journal:  Stat Med       Date:  2015-03-16       Impact factor: 2.373

4.  Delta inflation: a bias in the design of randomized controlled trials in critical care medicine.

Authors:  Scott K Aberegg; D Roxanne Richards; James M O'Brien
Journal:  Crit Care       Date:  2010-04-29       Impact factor: 9.097

5.  A post hoc evaluation of a sample size re-estimation in the Secondary Prevention of Small Subcortical Strokes study.

Authors:  Leslie A McClure; Jeff M Szychowski; Oscar Benavente; Robert G Hart; Christopher S Coffey
Journal:  Clin Trials       Date:  2016-04-19       Impact factor: 2.486

Review 6.  Axes of a revolution: challenges and promises of big data in healthcare.

Authors:  Smadar Shilo; Hagai Rossman; Eran Segal
Journal:  Nat Med       Date:  2020-01-13       Impact factor: 53.440

7.  Unplanned adaptations before breaking the blind.

Authors:  Martin Posch; Michael A Proschan
Journal:  Stat Med       Date:  2012-06-27       Impact factor: 2.373

8.  PXL01 in sodium hyaluronate for improvement of hand recovery after flexor tendon repair surgery: randomized controlled trial.

Authors:  Monica E Wiig; Lars B Dahlin; Jan Fridén; Lars Hagberg; Sören E Larsen; Kerstin Wiklund; Margit Mahlapuu
Journal:  PLoS One       Date:  2014-10-23       Impact factor: 3.240

9.  A tutorial on pilot studies: the what, why and how.

Authors:  Lehana Thabane; Jinhui Ma; Rong Chu; Ji Cheng; Afisi Ismaila; Lorena P Rios; Reid Robson; Marroon Thabane; Lora Giangregorio; Charles H Goldsmith
Journal:  BMC Med Res Methodol       Date:  2010-01-06       Impact factor: 4.615

10.  The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design.

Authors:  Munyaradzi Dimairo; Philip Pallmann; James Wason; Susan Todd; Thomas Jaki; Steven A Julious; Adrian P Mander; Christopher J Weir; Franz Koenig; Marc K Walton; Jon P Nicholl; Elizabeth Coates; Katie Biggs; Toshimitsu Hamasaki; Michael A Proschan; John A Scott; Yuki Ando; Daniel Hind; Douglas G Altman
Journal:  Trials       Date:  2020-06-17       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.